Market Cap
$19.4M
QNRX
Quoin Pharmaceuticals Ltd.
$3.90 ▼ -3.23%
Prev close $4.03Market cap$19.4M
ConsensusStrong Buy
12-mo target$20.71 (+431.1%)
▲ Bullish
Analyst conviction 9/10
Insider Buying Cluster (4 insiders)5 New Institutional Positions Biotech & Drug Discovery
Snapshot
The big-picture read on QNRX right now — valuation, ownership and activity at a glance.
Cap Size
Nano Cap
Analyst Consensus
Strong Buy (90%)
Inst. Holders
7 funds
Inst. Value
$1.5M
Inst. Activity
5 buys / 0 sells
Insider Activity
$280.0K buy / $0.00 sell
Insider Net $
$280.0K
SEC Reports
10
Press Releases
4
Price chart 30d -44.4%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 12, 2026 SEC Aug 28, 2026 Press
BTIG initiates coverage on QNRX at Buy
ANALYST-UPGRADE — Impact 4/10
Oct 6, 2026 other
Sep 2, 2026 SEC Quoin Pharmaceuticals Announces Acceptance of QRX003 Paper in Dermatology and Therapy
Quoin's paper on QRX003 mechanism of action and a pediatric Netherton Syndrome case report accepted
Three insiders at Quoin Pharmaceuticals (CEO, CFO, and a Director) made open-market purchases totaling $180K at $4.88/sh
CLUSTER — Impact 6/10
Aug 31, 2026 Insider
Culverwell Anthony James bought 6,146 shares
Director @ $4.88 ($30.0K)
Aug 31, 2026 Insider
Culverwell Anthony James bought 3,073 shares
Director
Aug 31, 2026 Insider
Aug 28, 2026 Press Lawlor Sally Bridget bought 10,244 shares
Chief Financial Officer @ $4.88 ($50.0K)
Quoin Pharmaceuticals announced a private placement raising up to ~$50M in gross proceeds, with ~$30.8M upfront from iss
Impact 7/10
Quoin Pharmaceuticals announced positive interim Phase 2/3 results for QRX003 in Netherton Syndrome: 4 of 6 patients (66
Impact 7/10
Analyst ratings buy % +2.3%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
90% rate it Buy or better · 10 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Oct 12, 2026 | BTIG | INITIATE | Buy | 53% |
| Sep 23, 2026 | Lake Street | INITIATE | Buy | 45% |
| May 4, 2026 | LUCID CAPITAL MARKETS | INITIATE | Buy | 36% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| Aug 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| Jul 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| Jun 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| May 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Apr 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Mar 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Feb 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% |
Price targets
Where 7 covering analysts think QNRX trades over the next 12 months.
$20.71 +431.1% upside Strong Buy
Current$3.90 Low$12.00 Median$20.00 High$35.00 7 analysts
$12.00$35.00
Analyst rating Strong Buy· 1.2/5 as of Oct 19, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
10 SEC filing reports analyzed · 3 bullish, 0 bearish, 2 mixed, 5 neutral · avg impact 3.7/10.Plus 4 press releases.
BULLISHANALYST-UPGRADE4/10
BTIG initiates coverage on QNRX at Buy
Oct 12, 2026
BULLISHANALYST-UPGRADE2/10
Lucid Capital Markets initiates QNRX at Buy with $30 PT — stock at $6.36, implying +372% upside
May 5, 2026
MIXEDCLUSTER6/10
Three insiders at Quoin Pharmaceuticals (CEO, CFO, and a Director) made open-market purchases totali
Sep 2, 2026
MIXED8-K6/10
Quoin Pharmaceuticals announced a $50M private placement (PIPE) of ADSs and warrants, including insi
Aug 28, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 6, 2026
other
Quoin Pharmaceuticals Announces Acceptance of QRX003 Paper in Dermatology and Therapy
Quoin's paper on QRX003 mechanism of action and a pediatric Netherton Syndrome case report accepted for publication in Dermatology and Therapy.
Sep 22, 2026
fda
Quoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin Syndrome
Quoin $QNRX receives FDA Fast Track Designation for QRX003 in Peeling Skin Syndrome, with a Phase 2/3 study expected to begin in 2H 2026.
Sep 8, 2026
fda
CORRECTION -- Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome
FDA grants Rare Pediatric Disease Designation to QRX003 for Peeling Skin Syndrome, Quoin's second RPD and a potential second Priority Review Voucher
Aug 31, 2026
ftd
FTD: QNRX — 182,046 shares ($1.1M) failed to deliver
Settlement: 20260831, Price: $6.12, FTD Value: $1,114,121.52, QUOIN PHARMACEUTICALS LTD SPON
Aug 28, 2026
offering
Quoin Pharmaceuticals Announces Private Placement Financing of Up to $50.0 Million
ASHBURN, Va., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical-stage specialty
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-1.76 | $-2.05–$-1.47 | 73.7% | +0.0% | 0↑ 1↓ | $0.0B | 2 |
| Next Q | $-1.81 | $-2.18–$-1.44 | — | +0.0% | 0↑ 1↓ | $0.0B | 2 |
| Current FY | $-7.17 | $-7.89–$-6.45 | — | +0.0% | 1↑ 1↓ | $0.0B | 2 |
| Next FY | $-3.19 | $-4.45–$-1.92 | 55.6% | +0.0% | 0↑ 1↓ | $0.0B | 2 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-1.760 | — |
| 7d ago | $-1.760 | — |
| 30d ago | $-1.760 | — |
| 60d ago | $-1.685 | -0.075 |
| 90d ago | $-1.685 | -0.075 |
Institutional ownership
Which big funds own QNRX (from quarterly 13F filings) and who is adding or trimming.
7 institutional holders with $1.5M total value (302,342 shares) as of 2026-Q2. Top holders: MILLENNIUM, Woodline, Aberdeen. Net buying activity: 5 institutions added/increased vs 0 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| MILLENNIUM MANAGEMENT LLC | 112,323 | $543.6K | 37.2% | ADD +47.3% |
| Woodline Partners LP | 76,446 | $370.0K | 25.3% | — |
| Aberdeen Group plc | 75,000 | $363.0K | 24.8% | — |
| BARCLAYS PLC | 21,469 | $103.9K | 7.1% | DOUBLED +1551.5% |
| MORGAN STANLEY | 8,000 | $38.7K | 2.6% | DOUBLED +100.0% |
| UBS Group AG | 6,772 | $32.8K | 2.2% | DOUBLED +169.6% |
| RHUMBLINE ADVISERS | 2,332 | $11.3K | 0.8% | ADD +53.3% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| MILLENNIUM MANAGEMENT LLC | ADD | 76,247 | 112,323 | +47.3% | $543.6K |
| BARCLAYS PLC | DOUBLED | 1,300 | 21,469 | +1551.5% | $103.9K |
| MORGAN STANLEY | DOUBLED | 4,000 | 8,000 | +100.0% | $38.7K |
| UBS Group AG | DOUBLED | 2,512 | 6,772 | +169.6% | $32.8K |
| RHUMBLINE ADVISERS | ADD | 1,521 | 2,332 | +53.3% | $11.3K |
| Centiva Capital, LP | DOUBLED | 12,053 | 60,000 | +397.8% | $396.0K |
| MORGAN STANLEY | ADD | 3,000 | 4,000 | +33.3% | $26.4K |
| UBS Group AG | DOUBLED | 17 | 2,512 | +14676.5% | $16.6K |
| RHUMBLINE ADVISERS | ADD | 1,210 | 1,666 | +37.7% | $24.0K |
| UBS Group AG | DOUBLED | 1 | 17 | +1600.0% | $245.00 |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
8 insiders, 18 transactions. Net $280.0K — $280.0K bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 31, 2026 | Culverwell Anthony James | Director | BUY | 6,146 | $4.88 | $30.0K |
| Aug 31, 2026 | Culverwell Anthony James | Director | BUY | 3,073 | — | — |
| Aug 31, 2026 | Lawlor Sally Bridget | Chief Financial Officer | BUY | 10,244 | $4.88 | $50.0K |
| Aug 31, 2026 | Lawlor Sally Bridget | Chief Financial Officer | BUY | 5,122 | — | — |
| Aug 31, 2026 | Myers Michael | Chief Executive Officer | BUY | 20,490 | $4.88 | $100.0K |
| Aug 31, 2026 | Myers Michael | Chief Executive Officer | BUY | 10,245 | — | — |
| Aug 31, 2026 | Carter Denise P. | Chief Operating Officer | BUY | 20,490 | $4.88 | $100.0K |
| Aug 31, 2026 | Carter Denise P. | Chief Operating Officer | BUY | 10,245 | — | — |
| Aug 27, 2026 | Culverwell Anthony James | Director | AWARD | 31,352 | $5.15 | $161.5K |
| Aug 27, 2026 | LANGER DENNIS | Director | AWARD | 34,534 | $5.15 | $177.9K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for QNRX.
Shares short
65,473
Settlement Sep 30, 2026
Change vs prior
-48.2%
Semi-monthly cycle
Days to cover
1.4
At avg daily volume
Of shares outstanding
≈1.4%
Estimate — not % of float
All QNRX filing & press-release reports (14)
- Lucid Capital Markets initiates QNRX at Buy with $30 PT — stock at $6.36, implying +372% upsideMay 5, 2026
- BTIG initiates coverage on QNRX at BuyOct 12, 2026
- CLUSTER reportSep 2, 2026
- 8-K reportAug 28, 2026
- PRESS-RELEASE reportAug 28, 2026
- PRESS-RELEASE reportAug 28, 2026
- 8-K reportAug 20, 2026
- PRESS-RELEASE reportAug 7, 2026
- 8-K reportJun 24, 2026
- PRESS-RELEASE reportMay 7, 2026
- PRESS-RELEASE reportApr 30, 2026
- PRESS-RELEASE reportMar 19, 2026
- 8-K reportMar 11, 2026
- PRESS-RELEASE reportMar 11, 2026